{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-082997","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.750826+00:00","generated_at":"2026-05-31T21:44:39.351995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M","bullets":["NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.","FY2024 net loss $126.6M ($3.44/share) vs $92.9M ($3.33) prior year; no revenue.","Cash, cash equivalents and marketable securities $210.4M, up from $149.4M; raised $150.1M net in Feb 2024 offering.","R&D expenses $86.2M (prior $80.3M); G&A $54.3M (prior $30.6M) driven by commercial planning and employee costs.","Promoted Benjamin Palleiko to CEO in March 2024; strategic review of preclinical Factor XIIa program ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-082997","json":"https://secwatch.observer/filing/0000950170-24-082997.json","markdown":"https://secwatch.observer/filing/0000950170-24-082997.md","text":"https://secwatch.observer/filing/0000950170-24-082997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/0000950170-24-082997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/kalv-20240711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:44:39.351995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}